Potential genotype-specific single nucleotide polymorphism interaction of common variation in p53 and its negative regulator mdm2 in cholangiocarcinoma susceptibility

  • Authors:
    • Vincent Zimmer
    • Aksana Höblinger
    • Florentina Mihalache
    • Gunter Assmann
    • Monica Acalovschi
    • Frank Lammert
  • View Affiliations

  • Published online on: April 17, 2012     https://doi.org/10.3892/ol.2012.680
  • Pages: 101-106
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Aberrant cell cycle control and apoptosis deregulation are involved in biliary carcinogenesis. The tumor suppressor gene p53 and its key negative regulator murine double minute 2 (mdm2) cooperate in modulating these basic cell functions and germline p53 alteration promotes cholangiocarcinoma (CCA) formation in animal models. The potential association between common functional genetic variation in p53 (SNP72 G/C) and mdm2 (SNP309 T/G) and susceptibility to bile duct cancer, however, has not been studied. p53/SNP72 G/C (rs1042522) and mdm2/SNP309 T/G (rs2279744) were genotyped in 182 Caucasian CCA patients and 350 controls using TaqMan assays. Allelic and genotypic differences, including exploratory data analyses (according to gender, tumor localization, early onset and genotypic interactions) were compared in contingency tables using the χ2 and Fisher's exact tests. The overall comparison of allele and genotype frequencies yielded no significant association between either SNP and CCA susceptibility. Similarly, gender- and localization-specific analyses did not reveal deviations in allelic or genotypic distributions. In carriers of the low-apoptotic p53 genotype CC, the mdm2 SNP309 T allele conferred borderline significant CCA risk [P=0.049; odds ratio (OR), 4.36; 95% CI, 0.92-20.77]. Power analysis confirmed adequate statistical power to exclude major SNP effects (each >97% for OR 1.7). Collectively, the results we obtained from the largest European CCA cohort do not support the hypothesis of a prominent role of common p53 and mdm2 variation in the genetic susceptibility to bile duct cancer. However, epistatic effects may modulate genetic CCA risk in individual subsets.

Introduction

Cholangiocarcinoma (CCA) is a highly malignant cancer with a poor prognosis which arises from the epithelial lining of intra- or extrahepatic bile ducts (1). CCA is the second most common primary liver malignancy and epidemiological studies have reported rising incidence rates in Western countries (2,3). Since clinical presentation and diagnosis at locally advanced and/or metastatic tumor stages beyond potential surgical cure are common, the reported 5-year survival rates rarely exceed 5–10%. Notwithstanding recent progress in treatment options for advanced CCA, alternative routes to improve the prognosis may include the identification and characterization of individuals at high risk of the disease, thus allowing for tumor surveillance and early diagnosis (46). Clinical risk factors include, among others, primary sclerosing cholangitis, viral hepatitis and liver fluke infections in Asian countries (7,8). However, knowledge of genetic susceptibility factors, with its potential to elucidate novel carcinogenic pathways and define high-risk populations, is limited, reflecting difficulties in establishing study cohorts of informative sample sizes for this rare cancer. We previously reported the increased genetic risk of CCA in α1 antitrypsin Z allele carriers, which was in accordance with previously published pathology-based data (911). Although the distinct molecular pathogenesis underlying malignant cholangiocyte transformation is poorly understood, chronic cholestasis and inflammation are considered to be key elements in CCA initiation (12). Recent studies have highlighted the carcinogenic role of the activation of nuclear factor κB (NF-κB) signaling in conferring resistance to apoptosis to malignant cholangiocytes; these findings substantiate the concept of CCA as an inflammation-driven cancer (13).

The p53 tumor suppressor network is a central component of cellular stress responses and is critical for the maintenance of genomic stability in response to various stresses, including DNA damage, metabolic perturbation and oncogene activation (14). Notably, p53 has been suggested to be a negative regulator of the proinflammatory transcription factor NF-κB (15,16). Deregulation of the p53 pathway by either overexpression or somatic mutation is a common feature in a number of types of human cancer, including CCA (1719). Furthermore, germline p53 alteration has been linked to CCA formation in animal models (20). Notably, common genetic variations, relevant to the p53 network and involved in cell cycle control and apoptosis regulation, have been identified (21). The single nucleotide polymorphism (SNP) c.309 T>G in the promoter/enhancer site of the murine double minute 2 (mdm2) gene, which is a critical negative regulator of p53 and is itself transcriptionally regulated by p53, affects the binding efficiency of the transcription factor SP1. Consequently, the SNP309 G allele has been suggested to translate into increased intracellular mdm2 levels, thereby limiting the cellular availability of functional p53 under stressful conditions (22). The p53 SNP c.72 G>C is located in a proline-rich domain and may affect the molecular structure of the p53 protein. This has been reported to have a functional impact, as the C allele is thought to induce apoptosis and suppress oncogene-induced transformation less efficiently (23).

Although these two genetic variants are among the most widely studied SNPs in genetic cancer research (21), no data are currently available for CCA. In this respect, the aim of the current study was to assess the potential contribution of the common functional gene variants p53 (SNP72 G/C) and mdm2 (SNP309 T/G) to the genetic susceptibility to bile duct cancer.

Patients and methods

Patient recruitment and characteristics

In total, 182 European CCA patients (103 males and 79 females) and 350 controls (151 males and 199 females) were recruited at equal case-control proportions at three academic medical centers in Germany and Romania. Specific aspects of the study population were reported in our previous study (9). Briefly, the clinical CCA diagnosis and classification criteria were in accordance with the recommendations of the British Society of Gastroenterology (24). There was a tissue diagnosis of CCA in 84% of the subjects, while in 16% of the patients the CCA diagnosis was based on clinical assessment, taking into account imaging studies, follow-up and exclusion of alternative diagnoses, including postoperative biliary strictures. The control subjects were recruited following either negative colorectal cancer screening (n=290) or normal liver ultrasound (n=60). Written informed consent was obtained from all participants. The study was approved by the respective ethics committees and was in accordance with the revised Declaration of Helsinki.

Genomic DNA isolation and genotyping

Following venipuncture and sampling of 5 ml whole blood, genomic DNA was extracted by standard techniques using a commercial kit (QIAamp, Qiagen, Hilden, Germany). Following appropriate spectrophotometric calibration of the DNA concentrations (NanoDrop ND-1000, NanoDrop Technologies, Wilmington, DE, USA), rs1042522 (p53 SNP72) and rs2279744 (mdm2 SNP309) were genotyped using solution-phase hybridization reactions with 5′-nuclease and fluorescence detection (TaqMan assays, Applied Biosystems, Foster City, CA, USA) on an ABI 7500 Fast Real-Time polymerase chain reaction (PCR) system (Applera, Norwalk, CT, USA). Specifically, the PCR assays contained 5 μl 2X Genotyping Mastermix, 0.25 μl 40X Genotyping mix, 3.75 μl H2O and 5–50 ng/μl DNA. The amplification conditions were as follows: 95°C for 10 min, 40 cycles of 95°C for 10 sec and 60°C for 1 min.

Statistical analysis

The data were analysed using the SPSS software package (version 17.0; SPSS, Munich, Germany). The age and gender structure of the study groups were analysed using t-tests. Data are shown as the mean ± SD. Genotypic data for the two SNPs were assessed for consistency with the Hardy-Weinberg equilibrium (HWE) in controls (P>0.05) using an exact test (http://ihg.gsf.de/snps.html). The allele and genotype frequencies of the study groups were compared using χ2-tests for 2×2 and 2×3 contingency tables. Fisher’s exact tests were used as appropriate, in particular for small sample sizes. Differences in allele and genotype distributions, including exploratory data analyses stratifying for gender, tumor localization, early onset and genotypic interactions, were assessed using odds ratios (ORs) and 95% confidence intervals (CIs). P<0.05 was considered statistically significant.

To assess for adequate sample size in our study, we performed power calculations using PS: Power and Sample Size Calculation v.3.0 (http://biostat.mc.vanderbilt.edu/wiki/Main/PowerSampleSize).

Results

Clinical parameters of the patients

Allelic discrimination for rs1042522 and rs2279744 was successful in all study subjects, yielding call rates of 100% for the two SNPs. The genotype distributions in the controls did not deviate from the Hardy-Weinberg equilibrium (P>0.05 for both SNPs). The detected allele frequencies were compatible with the Entrez SNP database entries (http://www.ncbi.nlm.nih.gov/snp). Of the cancer group, 57% of the patients were male, compared with 43% in the control group (P<0.01). The median age at CCA diagnosis/study entry was 65.8±11.4 years for cancer patients and 61.0±11.1 years for the control subjects (P<0.01). There were more patients with tumors arising from the extrahepatic biliary system than from intrahepatic localizations (141 extrahepatic vs. 41 intrahepatic localizations). The demographic and clinical data of the study population reflecting the epidemiology of CCA are shown in Table I.

Table I

Demographic and clinical parameters of the study population.

Table I

Demographic and clinical parameters of the study population.

ParametersCCAControlsP-value
Subjects (n)182350
Age, years (mean ± SD)65.8±11.461.0±11.1<0.01
Gender, male/female (%)103/79 (57/43)151/199 (43/57)<0.01
Localization, intra-/extrahepatic (%)41/141 (23/77)
Diagnosis, tissue/clinical (%)152/30 (84/16)

[i] CCA, cholangiocarcinoma.

Effect of allelic and genotypic distributions in the study groups

A comparison of the allelic distributions yielded no significant differences in either SNP between the study groups (SNP72, 27.2 vs. 26.9%; SNP309, 37.4 vs. 36.1% in CCA patients vs. controls, respectively). Similarly, no significant difference or marked trend was noted when analyzing genotypic distributions in the total study groups (Table II). We then evaluated the potential of specific SNP effects in terms of parameters such as gender, tumor localization (extra- vs. intrahepatic) and early onset CCA, arbitrarily defined as CCA diagnosis <60 years. Similarly, in this exhaustive exploratory data analysis no association signal was obtained for either SNP (data not shown).

Table II

Allele and genotype frequencies of p53 SNP72 and mdm2 SNP309 in CCA vs. controls.

Table II

Allele and genotype frequencies of p53 SNP72 and mdm2 SNP309 in CCA vs. controls.

Frequency typeCCA n (%)Controls n (%)P-value
Alleles
p53 SNP72G265 (72.8)512 (73.1)0.92
C99 (27.2)188 (26.9)(0.98)a
364 (100)700 (100)[0.74–1.31]b
mdm2 SNP309T228 (62.6)447 (63.9)0.70
G36 (37.4)253 (36.1)(0.95)a
364 (100)700 (100)[0.73–1.23]b
Genotypes
p53 SNP72GG94 (51.7)190 (54.3)0.49
GC77 (42.3)132 (37.7)(1.42)c
CC1 (6.0)28 (8.0)
182 (100)350 (100)
mdm2 SNP309TT74 (40.7)141 (40.3)0.62
TG80 (44.0)165 (47.1)(0.97)c
GG28 (15.3)44 (12.6)
182 (100)350 (100)

a Odds ratio;

b 95% confidence interval;

c χ2 for 2×3 contingency tables.

{ label (or @symbol) needed for fn[@id='tfn5-ol-04-01-0101'] } SNP, single nucleotide polymorphism; mdm, murine double minute; CCA, cholangiocarcinoma.

Effects of epistatic SNP

As the two variants under investigation are known to be functionally coupled, we explored the epistatic SNP effects. The results revealed a trend for the overrepresentation of SNP309 TT in carriers of the variant SNP72 genotype CC (81.8 vs. 50.0%; Fisher’s exact test P=0.24; Table III). In agreement with this trend, the allelic distributions reached borderline significance for T allele positivity in SNP72 CC homozygotes (90.9 vs. 69.6%; OR, 4.36; 95% CI, 0.92–20.77; P=0.049; Table IV). The statistical power was calculated, and sufficient power (>97% each) to pinpoint allelic association signals beyond ORs >1.7 for the two SNPs was identified (Fig. 1).

Table III

Genotypic interaction between p53 and mdm2 variants.

Table III

Genotypic interaction between p53 and mdm2 variants.

GenotypesCCA n (%)Controls n (%)P-value
p53 SNP72
 GGSNP30994 (100)190 (100)0.74
TT34 (36.2)69 (36.3)(0.6)a
TG44 (46.8)95 (50.0)
GG16 (17.0)26 (13.7)
 GCSNP30977 (100)132 (100)0.66
TT31 (40.3)58 (43.9)(0.83)a
TG34 (44.1)59 (44.7)
GG12 (15.6)15 (11.4)
 CCSNP30911 (100)28 (100)0.24b
TT9 (81.8)14 (50.0)
TG2 (18.2)11 (39.3)
GG0 (0)3 (10.7)
mdm2 SNP309
 TTSNP7274 (100)141 (100)0.85
GG34 (36.2)69 (49.0)(0.32)a
GC31 (46.8)58 (41.1)
CC9 (17.0)14 (9.9)
 TGSNP7280 (100)165 (100)0.29
GG44 (40.3)95 (57.5)(2.47)a
GC34 (44.1)59 (35.8)
CC2 (15.6)11 (6.7)
 GGSNP7228 (100)44 (100)0.38b
GG16 (81.8)26 (59.1)
GC12 (18.2)15 (34.1)
CC0 (0)3 (6.8)

a χ2 for 2×3 contingency tables;

b Fisher’s exact test;

{ label (or @symbol) needed for fn[@id='tfn8-ol-04-01-0101'] } SNP, single nucleotide polymorphism; mdm, murine double minute; CCA, cholangiocarcinoma.

Table IV

Allelic interaction between p53 and mdm2 variants.

Table IV

Allelic interaction between p53 and mdm2 variants.

GenotypesCCA n (%)Controls n (%)P-value
p53 SNP72
 GGSNP309
T112 (59.6)223 (58.7)0.86
G76 (40.4)147 (38.7)(1.03)a
188 (100)380 (100)[0.72–1.47]b
 GCSNP309
T96 (62.3)175 (66.3)0.41
G58 (37.7)89 (33.7)(0.84)a
154 (100)264 (100)[0.56–1.27]b
 CCSNP309
T20 (90.9)39 (69.6)0.049
G2 (9.1)17 (30.4)(4.36)a
22 (100)56 (100) [0.92–20.77]b
mdm2 SNP309
 TTSNP72
G99 (66.9)196 (69.5)0.58
C49 (33.1)86 (30.5)(0.89)a
148 (100)282 (100)[0.58–1.36]b
 TGSNP72
G122 (76.3)249 (75.5)0.84
C38 (23.7)81 (24.5)(0.96)a
160 (100)330 (100)[0.62–1.49]b
 GGSNP72
G44 (78.6)67 (76.1)0.74
C12 (21.4)21 (23.9)(0.87)a
56 (100)88 (100)[0.39–1.95]b

a Odds ratio;

b 95% confidence interval.

{ label (or @symbol) needed for fn[@id='tfn11-ol-04-01-0101'] } SNP, single nucleotide polymorphism; mdm, murine double minute; CCA, cholangiocarcinoma.

Discussion

Given the relative rarity of bile duct cancer and the ensuing lack of informative study populations, there is a paucity of information concerning genetic risk factors for CCA development. As yet, CCA is one of the few cancer types for which no genome-wide association study (GWAS) is available (25). Using a multi-institutional approach we have established a cohort comprising 182 cancer patients, which is currently the largest European-based cohort. However, this sample size may still be regarded as limited with respect to genetic association studies (26). In consideration of our overall negative association signals for either SNP, power estimations were important to ascertain adequate sample size. In our study, the study power exceeded 97% for the two variants with an OR set at 1.7, thus reasonably excluding major SNP effects in CCA susceptibility. The study power to firmly refute associations within distinct exploratory subgroups was limited, meaning that specific risk modulations for subsets of patients may not have been detectable in our data set. For example, there are data indicating gender-specific effects of SNP309 in the mdm2 promoter, which has been suggested to be regulated by estrogens (2729). Moreover, the two SNPs have been reported to modulate the age of onset in certain types of cancer, e.g., in head and neck and hereditary non-polyposis colorectal cancer (HNPCC) (30,31). Bile duct cancer is characterized by late onset, with a median age at diagnosis of >70 years, which is compatible with the age structure of our study population (32).

However, we observed a potential genotype-specific interaction between p53 SNP72 and mdm2 SNP309. Specifically, in the presence of the apoptosis-deficient p53 variant genotype SNP72 CC, the mdm2 SNP309 major allele T increased the genetic risk of CCA (P=0.049; OR, 4.36; 95% CI, 0.92–20.77). Thus, it appears that in this specific genotypic context the relative attenuation of cellular mdm2 availability (related to the T allele of SNP309) with increased degradation of variant p53 in SNP72 CC homozygous individuals may result in the SNP309 T variant becoming a risk allele. In this respect, it should be noted that, beyond its low-apoptotic capacity, the C allele of p53 SNP72 has been reported to be a stronger inducer of transcription and cell-cycle arrest. These are potential pro-oncogenic effects that may become relevant in a genetic setting of less effective p53 suppression mediated by the mdm2 SNP309 T variant (33,34). However, the association signal was weak and based on a limited number of individuals. With regard to such complex gene-gene interactions, further confirmatory studies in larger cohorts are necessary to ascertain such epistatic SNP effects.

In conclusion, our data do not support the hypothesis of a prominent role of p53 SNP72 and mdm2 SNP309 in the genetic architecture of bile duct cancer. A subtle risk modulation by specific genotype-specific interactions of these functionally coupled genes may modify CCA susceptibility and this requires confirmatory studies in different cohorts.

Acknowledgements

This study was supported by HOMFOR (to V.Z.) and preliminary results were presented, in part, at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA, USA, in October 2009.

References

1 

Khan SA, Thomas HC, Davidson BR and Taylor-Robinson SD: Cholangiocarcinoma. Lancet. 366:1303–1314. 2005. View Article : Google Scholar : PubMed/NCBI

2 

Shaib Y and El-Serag HB: The epidemiology of cholangiocarcinoma. Semin Liver Dis. 24:115–125. 2004. View Article : Google Scholar : PubMed/NCBI

3 

Cardinale V, Semeraro R, Torrice A, et al: Intra-hepatic and extra-hepatic cholangiocarcinoma: new insight into epidemiology and risk factors. World J Gastrointest Oncol. 2:407–416. 2010. View Article : Google Scholar : PubMed/NCBI

4 

Valle J, Wasan H, Palmer DH, et al: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 362:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI

5 

Hezel AF, Deshpande V and Zhu AX: Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol. 28:3531–3540. 2010. View Article : Google Scholar : PubMed/NCBI

6 

Ortner MA: Photodynamic therapy for cholangiocarcinoma: overview and new developments. Curr Opin Gastroenterol. 25:472–476. 2009. View Article : Google Scholar : PubMed/NCBI

7 

Gatto M, Bragazzi MC, Semeraro R, et al: Cholangiocarcinoma: update and future perspectives. Dig Liver Dis. 42:253–260. 2010. View Article : Google Scholar : PubMed/NCBI

8 

Blechacz BR and Gores GJ: Cholangiocarcinoma. Clin Liver Dis. 12:131–150. 2008. View Article : Google Scholar

9 

Mihalache F, Hoblinger A, Grunhage F, et al: Heterozygosity for the alpha1-antitrypsin Z allele may confer genetic risk of cholangiocarcinoma. Aliment Pharmacol Ther. 33:389–394. 2011. View Article : Google Scholar : PubMed/NCBI

10 

Zhou H, Ortiz-Pallardo ME, Ko Y and Fischer HP: Is heterozygous alpha-1-antitrypsin deficiency type PIZ a risk factor for primary liver carcinoma? Cancer. 88:2668–2676. 2000. View Article : Google Scholar : PubMed/NCBI

11 

Hoblinger A and Lammert F: Genetics of biliary tract diseases: new insights into gallstone disease and biliary tract cancers. Curr Opin Gastroenterol. 24:363–371. 2008. View Article : Google Scholar : PubMed/NCBI

12 

Blechacz B and Gores GJ: Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology. 48:308–321. 2008. View Article : Google Scholar : PubMed/NCBI

13 

Grivennikov SI, Greten FR and Karin M: Immunity, inflammation, and cancer. Cell. 140:883–899. 2010. View Article : Google Scholar

14 

Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI

15 

Komarova EA, Krivokrysenko V, Wang K, et al: p53 is a suppressor of inflammatory response in mice. FASEB J. 19:1030–1032. 2005.PubMed/NCBI

16 

Gudkov AV and Komarova EA: Dangerous habits of a security guard: the two faces of p53 as a drug target. Hum Mol Genet. 16(Spec No 1): R67–R72. 2007. View Article : Google Scholar : PubMed/NCBI

17 

Khan SA, Taylor-Robinson SD, Carmichael PL, Habib N, Lemoine NR and Thomas HC: Analysis of p53 mutations for a mutational signature in human intrahepatic cholangiocarcinoma. Int J Oncol. 28:1269–1277. 2006.PubMed/NCBI

18 

Khan SA, Thomas HC, Toledano MB, Cox IJ and Taylor-Robinson SD: p53 Mutations in human cholangiocarcinoma: a review. Liver Int. 25:704–716. 2005. View Article : Google Scholar : PubMed/NCBI

19 

Tannapfel A, Weinans L, Geissler F, et al: Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver. Dig Dis Sci. 45:317–324. 2000. View Article : Google Scholar : PubMed/NCBI

20 

Farazi PA, Zeisberg M, Glickman J, Zhang Y, Kalluri R and DePinho RA: Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Cancer Res. 66:6622–6627. 2006. View Article : Google Scholar : PubMed/NCBI

21 

Whibley C, Pharoah PD and Hollstein M: p53 polymorphisms: cancer implications. Nat Rev Cancer. 9:95–107. 2009. View Article : Google Scholar : PubMed/NCBI

22 

Bond GL, Hu W, Bond EE, et al: A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 119:591–602. 2004. View Article : Google Scholar : PubMed/NCBI

23 

Dumont P, Leu JI, Della Pietra AC III, George DL and Murphy M: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 33:357–365. 2003. View Article : Google Scholar : PubMed/NCBI

24 

Khan SA, Davidson BR, Goldin R, et al: Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut. 51(Suppl 6): 1–9. 2002.PubMed/NCBI

25 

Hartman M, Loy EY, Ku CS and Chia KS: Molecular epidemiology and its current clinical use in cancer management. Lancet Oncol. 11:383–390. 2010. View Article : Google Scholar : PubMed/NCBI

26 

Hattersley AT and McCarthy MI: What makes a good genetic association study? Lancet. 366:1315–1323. 2005. View Article : Google Scholar : PubMed/NCBI

27 

Bond GL, Hirshfield KM, Kirchhoff T, et al: MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res. 66:5104–5110. 2006. View Article : Google Scholar : PubMed/NCBI

28 

Bond GL and Levine AJ: A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene. 26:1317–1323. 2007. View Article : Google Scholar

29 

Zimmer V, Widmann T, Muller M, et al: Genotypic interaction and gender specificity of common genetic variants in the p53/mdm2 network in Crohn’s disease. Digestion. 81:246–251. 2010.PubMed/NCBI

30 

Jones JS, Chi X, Gu X, Lynch PM, Amos CI and Frazier ML: p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Clin Cancer Res. 10:5845–5849. 2004. View Article : Google Scholar : PubMed/NCBI

31 

Shen H, Zheng Y, Sturgis EM, Spitz MR and Wei Q: P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett. 183:123–130. 2002. View Article : Google Scholar : PubMed/NCBI

32 

Welzel TM, Graubard BI, El-Serag HB, et al: Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol. 5:1221–1228. 2007. View Article : Google Scholar : PubMed/NCBI

33 

Thomas M, Kalita A, Labrecque S, Pim D, Banks L and Matlashewski G: Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 19:1092–1100. 1999.PubMed/NCBI

34 

Pim D and Banks L: p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer. 108:196–199. 2004. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

July 2012
Volume 4 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zimmer V, Höblinger A, Mihalache F, Assmann G, Acalovschi M and Lammert F: Potential genotype-specific single nucleotide polymorphism interaction of common variation in p53 and its negative regulator mdm2 in cholangiocarcinoma susceptibility. Oncol Lett 4: 101-106, 2012
APA
Zimmer, V., Höblinger, A., Mihalache, F., Assmann, G., Acalovschi, M., & Lammert, F. (2012). Potential genotype-specific single nucleotide polymorphism interaction of common variation in p53 and its negative regulator mdm2 in cholangiocarcinoma susceptibility. Oncology Letters, 4, 101-106. https://doi.org/10.3892/ol.2012.680
MLA
Zimmer, V., Höblinger, A., Mihalache, F., Assmann, G., Acalovschi, M., Lammert, F."Potential genotype-specific single nucleotide polymorphism interaction of common variation in p53 and its negative regulator mdm2 in cholangiocarcinoma susceptibility". Oncology Letters 4.1 (2012): 101-106.
Chicago
Zimmer, V., Höblinger, A., Mihalache, F., Assmann, G., Acalovschi, M., Lammert, F."Potential genotype-specific single nucleotide polymorphism interaction of common variation in p53 and its negative regulator mdm2 in cholangiocarcinoma susceptibility". Oncology Letters 4, no. 1 (2012): 101-106. https://doi.org/10.3892/ol.2012.680